Log on / register
Feedback | Support | My details
The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.
Kokkonen H, Johansson M, Innala L, Jidell E, Rantapää-Dahlqvist S
Arthritis Res Ther 2007, 9:R56
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Research article
Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy
Nicaise Roland P, Grootenboer Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G, Dieudé P, Meyer O, Chollet Martin S
Arthritis Research & Therapy 2008, 10:R142 (10 December 2008)
[Full text] [PubMed Central] [PubMed] [Related articles] [Cited on BioMed Central]
2.


Research article
Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking
Costenbader KH, Chang SC, De Vivo I, Plenge R, Karlson EW
Arthritis Research & Therapy 2008, 10:R52 (7 May 2008)
[Full text] [PubMed Central] [PubMed] [Related articles] [Cited on BioMed Central]
3.


Correction
Correction: The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden
Kokkonen H, Johansson M, Innala L, Jidell E, Rantapää-Dahlqvist S
Arthritis Research & Therapy 2007, 9:403 (25 October 2007)

You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.